The peripheral liquid embolic agents market size is projected to reach US$ 81.41 million by 2031 from US$ 40.42 million in 2023. The market is expected to register a CAGR of 9.1% during 2023–2031. The growing focus and developments in temperature-induced phase change systems and pH-triggered embolic agents are likely to bring new trends in the peripheral liquid embolic agents market
Liquid embolic agents are used primarily in minimally invasive procedures, such as embolization, for treating aneurysms, arteriovenous malformations, tumors, and other conditions. These agents provide a less invasive alternative to traditional surgical methods and allow physicians greater control and precision in closing blood vessels while minimizing patient trauma and recovery times. Technological innovations are expected to improve product performance and promote broader adoption in various downstream applications. Furthermore, the peripheral liquid embolic agents market is growing because of the increasing adoption and acceptance by patients and healthcare professionals owing to the increasing awareness of the benefits provided by liquid embolic agents in the treatment of peripheral vascular diseases.
Liquid embolic agents are used to treat peripheral vascular diseases such as varicocele and peripheral artery embolization. The market for these agents is driven by the increasing preference of patients and healthcare professionals for minimally invasive procedures. The introduction of the latest medical technology, such as liquid embolic agents, supported by rising healthcare expenditure globally and improving healthcare infrastructure in emerging markets, is driving the peripheral liquid embolic agents market expansion. In addition, favorable reimbursement practices for minimally invasive procedures using liquid embolic agents in many countries are promoting their acceptance and driving market expansion.
Peripheral vascular disease (PVD) consists of peripheral arterial disease (PAD) and venous disease. The growing prevalence of PVD can be attributed to the proliferating aging population that increases the visibility of its various diagnostic and treatment modalities. According to the article “Income-Related Peripheral Artery Disease Treatment,” published in the National Library of Medicine, more than 200 million people across the world suffer from PAD, and ~10% of people aged 50 years and above have been affected by the disease in Western Europe and North America. The prevalence of PVD ranges from 3% in patients aged >55 years and 11% in patients aged >65 years to 20% in patients aged >75. According to a study published in the National Library of Medicine titled "Secular Trends in the Epidemiological Patterns of Peripheral Artery Disease and Risk Factors in China," the number of people suffering from peripheral arterial disease in China increased by 40% between 2000 and 2020. In 2020, ~41 million adults in China were affected by PAD. In 2020, epidemiological research in China also found that the prevalence of PAD in the general population aged 35 years and above was 6%, and the prevalence of PAD in elderly over 60 years of age was 15% in China. It is estimated that there are more than 30 million patients suffering from peripheral artery disease in the country.
The rising prevalence of PVD is attributed to the increasing risk factors associated with diabetes, smoking, obesity, and age. With unhealthy lifestyle changes and the availability of medications not enough to treat PVD symptoms, minimally invasive procedures using peripheral stents are often the standard treatment. Cerebrovascular/carotid disease, peripheral arterial disease, and abdominal aortic aneurysms are among the most common peripheral vasculopathies reported by primary care physicians. All require aggressive medical treatment to prevent potentially serious complications and require vascular surgeons for evaluation. Liquid embolic agents are usually injected and introduced into the vascular malformation sites using a catheter guided by X-ray imaging (i.e., angiography). After infusion of the liquid embolic agents, it changes into a solid implant in situ, based on different mechanisms, including precipitation, polymerization, and cross-linking, through ionic or thermal processes. Liquid embolic agents do not rely on the patient's coagulation system for complete occlusion and may be effective even in patients suffering from severe coagulopathy. If a catheter cannot reach a bleeding site, liquid agents can provide embolization distal to the catheter tip. Long-term treatment strategies, better outcomes, and regulations to reduce cardiovascular mortality are recommended by all major regions, comprising the European Society of Cardiology (ESC), the European Society for Vascular Surgery (ESVS), the American Heart Association (AHA), and American College of Cardiology (ACC). Therefore, the growing prevalence of PVD drives the peripheral liquid embolic agents market growth.
Market players are constantly focusing on maintaining their leadership position in the market by continuously working toward strategic initiatives, introducing new products, and improving the existing products to broaden the usage of peripheral liquid embolic agents.
Thus, new product launches based on advancements and strategic initiatives are likely to provide new opportunities for the peripheral liquid embolic agents market in the coming years.
Key segments that contributed to the derivation of the peripheral liquid embolic agents market analysis are type and application.
The geographic scope of the peripheral liquid embolic agents market report is mainly divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America.
North America holds the largest share of the peripheral liquid embolic agents market. The regional market growth is propelled by the increasing incidence of vascular diseases, growing strategic initiatives by the market players, supportive government plans, and the development of innovative liquid embolic products. Canada held the largest share of the peripheral liquid embolic agents market in North America in 2023. The market is expected to grow owing to the availability of advanced healthcare infrastructure and rising incidence of target conditions. However, Asia Pacific is expected to register the highest CAGR during 2023–2031. The Asia Pacific market growth is driven by various factors such as the rising prevalence of peripheral artery diseases (PAD), increasing demand for minimally invasive procedures, growing number of hospitals and ambulatory surgery centers, market players are focusing on developing countries for growth opportunities, and developing healthcare infrastructure in Asia Pacific. In the region, China held the largest market share in 2023 as the market players in China are engaged in strategic activities to expand their footprint in the market. In May 2021, Grand Pharmaceutical and Healthcare Holdings Limited acquired Shenming Medical Technology Co., Ltd. The company obtained all rights of an innovative thermosensitive embolic agent that is used for liver cancer treatment, further expanding the tumor intervention treatment product pipeline.
The regional trends and factors influencing the Peripheral Liquid Embolic Agents Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Peripheral Liquid Embolic Agents Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 40.42 Million |
| Market Size by 2031 | US$ 81.41 Million |
| Global CAGR (2023 - 2031) | 9.1% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Peripheral Liquid Embolic Agents Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Peripheral Liquid Embolic Agents Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The peripheral liquid embolic agents market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the peripheral liquid embolic agents market are listed below:
The “Peripheral Liquid Embolic Agents Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:
The List of Companies - Peripheral Liquid Embolic Agents Market
The market is estimated to reach US$ 81.41 million by 2031.
North America dominated the market in 2023.
The rising incidence of peripheral vascular diseases and upsurging demand for minimally invasive procedures are among the factors driving the market.
Medtronic, Gem Srl, MicroVention Inc, Johnson and Johnson, and Balt are among the leading players operating in the market.
The growing focus and developments in temperature-induced phase change systems and pH-triggered embolic agents are likely to bring new trends in the market.
The market is expected to register a CAGR of 9.1% during 2023–2031.